Literature DB >> 8282570

Renal immunolocalization of kallikrein in cisplatin nephrotoxicity in rats.

C Orfila1, G Bompart, J C Lepert, J M Suc, J P Girolami.   

Abstract

Treatment of rats with cisplatin (4 mg kg-1 body wt i.p. injection) induced variations of urinary kallikrein excretion (UKE). Three phases were observed: a transient increase of UKE one day after injection, followed by a decrease up to 10 days suggesting an altered biosynthesis and a recovery phase with return to normal control values, 21 days after injection. Early morphological lesions were observed in proximal tubule cells on day 1; severe changes and tubular necrosis were observed in the following days. Less marked changes were also present in distal tubules but the vacuolated and desquamated cells appeared in the lumen of the tubules. By immunocytochemical methods, kallikrein was observed in connecting tubule cells, but also in some proximal tubule cells and along the endothelial side of the glomerular basement membrane and urinary space of glomeruli. An intense labelling was present in desquamated epithelial cells in dilated lumen of tubules. This study provides evidence of the presence of immunoreactive kallikrein in the glomerulus, already reported during acute failure, and confirms the use of urinary kallikrein measurements as a useful non-invasive index to assess a possible nephrotoxic effect at the distal level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8282570     DOI: 10.1007/BF00211772

Source DB:  PubMed          Journal:  Histochem J        ISSN: 0018-2214


  30 in total

1.  Mild renal failure induced by subchronic exposure to molybdenum: urinary kallikrein excretion as a marker of distal tubular effect.

Authors:  G Bompart; C Pécher; D Prévot; J P Girolami
Journal:  Toxicol Lett       Date:  1990-08       Impact factor: 4.372

2.  Platinum compounds: a new class of potent antitumour agents.

Authors:  B Rosenberg; L VanCamp; J E Trosko; V H Mansour
Journal:  Nature       Date:  1969-04-26       Impact factor: 49.962

3.  Subcellular localization of renal kallikrein by ultrastructural immunocytochemistry.

Authors:  C P Vío; C D Figueroa
Journal:  Kidney Int       Date:  1985-07       Impact factor: 10.612

4.  Inverse relationship between renal and urinary kallikrein during chromate-induced acute renal failure in rat: urinary kallikrein excretion as a possible recovery index.

Authors:  J P Girolami; C Orfila; C Pecher; G Cabos-Boutot; J L Bascands; J P Moatti; A Adam; A Colle
Journal:  Biol Chem Hoppe Seyler       Date:  1989-12

5.  Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations.

Authors:  D C Dobyan; J Levi; C Jacobs; J Kosek; M W Weiner
Journal:  J Pharmacol Exp Ther       Date:  1980-06       Impact factor: 4.030

6.  Functional and histopathological changes in dog kidneys after administration of cisplatin.

Authors:  G Daugaard; U Abildgaard; S Larsen; N H Holstein-Rathlou; O Amtorp; H P Olesen; P P Leyssac
Journal:  Ren Physiol       Date:  1987

Review 7.  The renal kallikrein-kinin system in human and in experimental hypertension.

Authors:  O A Carretero; A G Scicli
Journal:  Klin Wochenschr       Date:  1978

8.  Kallikrein localization in rodent salivary glands and kidney with the immunoglobulin-enzyme bridge technique.

Authors:  J A Simson; S S Spicer; J Chao; L Grimm; H S Margolius
Journal:  J Histochem Cytochem       Date:  1979-12       Impact factor: 2.479

9.  Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat. Correlation of structural and functional alterations.

Authors:  T W Jones; S Chopra; J S Kaufman; W Flamenbaum; B F Trump
Journal:  Lab Invest       Date:  1985-04       Impact factor: 5.662

View more
  1 in total

1.  The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney.

Authors:  Kritika Ramani; Abhishek V Garg; Chetan V Jawale; Heather R Conti; Natasha Whibley; Edwin K Jackson; Sruti S Shiva; William Horne; Jay K Kolls; Sarah L Gaffen; Partha S Biswas
Journal:  PLoS Pathog       Date:  2016-11-04       Impact factor: 6.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.